ライフサイエンスコーパス: outcome research

1 ormal lipid levels requires further clinical outcome research.

2 ry roles of randomized controlled trials and outcome research.

3 ncreasingly important in clinical trials and outcome research.

4 cts affect the generalizability of treatment outcome research.

5 nd of PTSD, and gold standards for treatment outcome research.

6 ical), epidemiological, and patient-centered outcome research.

7 riable of interest in traumatic brain injury outcome research.

8 s widely applicable to the field of surgical outcomes research.

9 The KDRI is widely used in kidney transplant outcomes research.

10 y in clinical practice, clinical trials, and outcomes research.

11 s of visual disability for use in ophthalmic outcomes research.

12 evaluating clinical programs or for clinical outcomes research.

13 nitalia is lending direction to longitudinal outcomes research.

14 deline development, medical informatics, and outcomes research.

15 for clinical trials, and 45 (6.5%) were for outcomes research.

16 s (ie, distance bias) and is a limitation in outcomes research.

17 pportunities to contribute to cardiovascular outcomes research.

18 nd a vision for the future of cardiovascular outcomes research.

19 ng for stroke severity is crucial for stroke outcomes research.

20 -stage investigators committed to careers in outcomes research.

21 to anyone with an interest in atopic eczema outcomes research.

22 provement programs, and peer-reviewed health outcomes research.

23 rofessional group dedicated to atopic eczema outcomes research.

24 s and to prioritize topics for atopic eczema outcomes research.

25 dvance collaborative high-yield, high-impact outcomes research; (2) identify priorities and barriers

26 ronmental chemicals for obesity and diabetes outcomes research: a screening approach using ToxCast hi

27 ding an examination of the recent history of outcomes research, an evaluation of the current academic

28 e of exclusion criteria in alcohol treatment outcome research and its effects on the comparability of

29 QOL research is an important element of outcomes research and can provide an important adjunct t

30 s, and Actions in Coronary Events Center for Outcomes Research and Education (TRACE-CORE) aims to adv

31 dicated by the 2013 Collaboration for Cancer Outcomes Research and Evaluation (CCORE) radiotherapy us

32 rate using the 2013 Collaboration for Cancer Outcomes Research and Evaluation model.

33 These findings have implications for TBI outcomes research and for protocols and research selecti

34 CER incorporates many attributes of outcomes research and health services research, while pl

35 r risk adjustment in population-based stroke outcomes research and in assessments of health system pe

36 ds This study used data from the Cancer Care Outcomes Research and Surveillance (CanCORS) consortium.

37 93 patients participating in the Cancer Care Outcomes Research and Surveillance (CanCORS) study (a na

38 ng or colorectal cancer from the Cancer Care Outcomes Research and Surveillance (CanCORS) study were

39 ed survey of participants in the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS)

40 , and prospective cohort studies Cancer Care Outcomes Research and Surveillance Consortium (CanCORS)

41 ve, observational study from the Cancer Care Outcomes Research and Surveillance Consortium from five

42 tion-based cohort studied by the Cancer Care Outcomes Research and Surveillance Consortium, and we ab

43 cancer who were enrolled in the Cancer Care Outcomes Research and Surveillance study (a multiregiona

44 lung or colorectal cancer in the Cancer Care Outcomes Research and Surveillance study (a multiregiona

45 Patients participating in the Cancer Care Outcomes Research and Surveillance study were interviewe

46 e Consortium for Dural Arteriovenous Fistula Outcomes Research and the International Radiosurgery Res

47 e research, translational research, clinical outcomes research, and even in prevention/control resear

48 may facilitate future clinical trial design, outcomes research, and patient care.

49 quelae of childhood asthma, patient-centered outcomes research, and precision medicine.

50 ies and barriers to important cardiovascular outcomes research; and (3) define future needs for the f

51 tions with individuals who have expertise in outcomes research; and (5) expansion of opportunities to

52 New techniques from the business and outcomes research arenas allow for the development of qu

53 ample, contributing to clinical research and outcomes research as well as health education and public

54 sing Baby-Measure of Neonatal Intensive Care Outcomes Research (Baby-MONITOR) for extremely and very

55 iction, however, should be validated through outcomes research before it is widely propagated.

56 l data in the context of clinical trials and outcomes research, but collection, documentation, and re

57 s a significant investment in cardiovascular outcomes research by the National Heart, Lung, and Blood

58 hould be conducted so that alcohol treatment outcome research can be better generalized to vulnerable

59 The Centers for Cardiovascular Outcomes Research (CCORs) held a meeting to review how c

60 om the National Institute for Cardiovascular Outcomes Research clinical registry.

61 thered and/or calculated utilizing the Sight Outcomes Research Collaborative (SOURCE) database and an

62 onversion to neovascular AMD using the Sight Outcomes Research Collaborative (SOURCE) database.

63 >=18 years who were documented in the Sight Outcomes Research Collaborative (SOURCE) repository to h

64 17.5 million lens exam records in the Sight Outcomes Research Collaborative (SOURCE) repository.

65 ter electronic health record database, Sight Outcomes Research Collaborative (SOURCE), was queried fo

66 ealth systems contributing data to the Sight Outcomes Research Collaborative Ophthalmology Data Repos

67 ulty falling sleeping in the Fatty Acids and Outcome Research Consortium.

68 studies that are part of the Fatty Acids and Outcomes Research Consortium participated in the analysi

69 Cumulative experience and ongoing outcomes research continue to substantiate the safety an

70 concluded that a dedicated investment in CV outcomes research could directly improve the care delive

71 The National Institute for Cardiovascular Outcomes Research database was used to identify adult ca

72 e obtained from the Cardinal Health Clinical Outcomes Research Database, a large population-based dat

73 Retrospective review of Cardinal Health Outcomes Research Database, which comprises all acute ca

74 prevention and treatment interventions, and outcomes research for patients and families.

75 held a meeting to review how cardiovascular outcomes research had evolved in the decade since the Na

76 In more recent times, outcome research has given us further information that r

77 However, asthma outcomes research has almost invariably concentrated on

78 Recent clinical outcomes research has examined the impact of blood trans

79 Advance care planning outcomes research has previously focused on seriously il

80 Many advances in outcomes research have been pioneered in transplantation

81 s an important tool for Health Economics and Outcomes Research (HEOR) evidence synthesis.

82 To facilitate comparative clinical outcome research in low vision rehabilitation, we must u

83 compute single-patient predictions in stroke outcome research in the acute, subacute and chronic stag

84 group of patients should be based on ongoing outcome research in this field.

85 Richard A and Susan F Smith Center for Outcomes Research in Cardiology, Hellman Family Foundati

86 Blood Institute convened a working group on outcomes research in cardiovascular disease (CVD).

87 marize the current state of patient-centered outcomes research in ILD, identify gaps in knowledge and

88 The Clinical Outcomes Research Initiative (CORI) receives endoscopy r

89 oscopy and pathology reports to the Clinical Outcomes Research Initiative repository.

90 etScan; Medicare; Medicaid; and the Clinical Outcomes Research Initiative's National Endoscopic Datab

91 The Patient-Centered Outcomes Research Institute (PCORI) has established dist

92 und of merit review for the Patient-Centered Outcomes Research Institute (PCORI) in November 2012 inc

93 and Affordable Care Act, a Patient-centered Outcomes Research Institute (PCORI) was established to a

94 nto law in 2010 created the Patient-Centered Outcomes Research Institute (PCORI), which includes an i

95 Patient-Centered Outcomes Research Institute and National Multiple Sclero

96 Patient-Centered Outcomes Research Institute and the National Multiple Sc

97 zed research agenda for the Patient-Centered Outcomes Research Institute as informed by a diverse gro

98 The Patient-Centered Outcomes Research Institute is funding 8 comparative eff

99 The Patient-Centered Outcomes Research Institute offers substantial funding t

100 The Patient-Centered Outcomes Research Institute tasked the Duke Evidence Syn

101 matic clinical trial by the Patient-Centered Outcomes Research Institute's National Patient-Centered

102 Patient-Centered Outcomes Research Institute, Dialysis Clinic, Kidney Res

103 Patient-Centered Outcomes Research Institute, Myasthenia Gravis Foundatio

104 s article will describe the Patient-Centered Outcomes Research Institute-funded asthma projects and h

105 oping review was based on a Patient-Centered Outcomes Research Institute-funded evidence map of Engli

106 ess Research (PROSPER) is a Patient-Centered Outcomes Research Institute-funded research program desi

107 Patient-Centered Outcomes Research Institute.

108 anagement developed for the Patient-Centered Outcomes Research Institute.

109 Research Foundation and the Patient-Centered Outcomes Research Institute.

110 liorate inflammation.FUNDINGPatient Centered Outcomes Research Institute; NIH; American Asthma Founda

111 (5) expansion of opportunities to train new outcomes research investigators.

112 Outcome research is deeply rooted in epidemiology, inclu

113 Outcomes research is a rapidly evolving field that incor

114 Health services and outcomes research is essential to inform gaps in care bu

115 A frequent challenge in outcomes research is the comparison of rates from differ

116 For the purposes of this document, "outcomes research" is defined as investigative endeavors

117 mized studies (a term that is preferable to "outcomes research") is in the allocation of patients to

118 rinciples of QOL research are similar to all outcomes research methods.

119 Despite the increasing interest in outcomes research, methods to develop COSs have not yet

120 and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR), 9306 research participant

121 40 participating sites from Patient-Centered Outcomes Research Network-a network of Clinical Data Res

122 Outcome research on psychological therapies for FND has

123 s use and associations with adverse neonatal outcomes, research on child neurodevelopmental outcomes

124 ted in literature with continuous and binary outcomes, research on its performance with time-to-event

125 providers for collaborative patient-centered outcomes research (PCOR).

126 practice, and is central to patient-centered outcomes research (PCOR).

127 zable, and are essential in patient-centered outcomes research (PCOR).

128 h established the Centers for Cardiovascular Outcomes Research program in 2010.

129 The Centers for Cardiovascular Outcomes Research program represents a significant inves

130 ry interventions to design successful health outcomes research programs.

131 Lastly, outcome research provides encouraging preliminary eviden

132 Conventional outcomes research provides only percentage risk of such

133 ng a database to address health services and outcomes research questions in critical care, examines s

134 o provide guidance on research priorities in outcomes research related to CVD.

135 ion criteria can result in alcohol treatment outcome research samples that are more heavily composed

136 ptimal care, further program development and outcomes research should target these bundle components

137 govern the conduct of burden-of-illness and outcomes research studies involving collaborations betwe

138 andomized trials, the Vioxx Gastrointestinal Outcomes Research Study (VIGOR; 8076 patients) and the C

139 y data retrieved from the Perinatal Neonatal Outcomes Research Study in the Arabian Gulf (PEARL-Peris

140 nts and outpatients in the Pneumonia Patient Outcomes Research Team (PORT) cohort study.

141 heir use conforms with Schizophrenia Patient Outcomes Research Team (PORT) recommendations for adjunc

142 graphically confirmed pneumonia of Pneumonia Outcomes Research Team (PORT) risk class II, III, or IV

143 y trial, adult Asian patients with Pneumonia Outcomes Research Team (PORT) risk class III-IV acute co

144 ults aged 18 years or older with a Pneumonia Outcomes Research Team (PORT) risk class of II, III, or

145 n was assessed using SMART-COP and Pneumonia Outcomes Research Team (PORT) scoring systems.

146 nity-acquired bacterial pneumonia (Pneumonia Outcomes Research Team [PORT] class II-IV) were randomiz

147 in the CPORT-E trial (Cardiovascular Patient Outcomes Research Team Non-Primary Percutaneous Coronary

148 9) receive ICU care in the Pneumonia Patient Outcomes Research Team prospective cohort.

149 e-blind study, adults with CABP of Pneumonia Outcomes Research Team risk class >=III were randomized

150 were adherence to the Schizophrenia Patient Outcomes Research Team treatment recommendations from in

151 te measure of staffing for nursing-sensitive outcomes research than administrative measures, as it re

152 tion to studies that use exclusion criteria, outcome research that uses no or minimal exclusion crite

153 d current use and examples of cardiovascular outcomes research that apply qualitative methods such as

154 factors, impact on cardiovascular outcomes, outcomes research that is currently in progress, and are

155 s of anger and aggression along with service outcome research, the criminal justice system, and a rou

156 tent criteria for future clinical trials and outcomes research, the CMV Resistance Working Group of t

157 keholders and a research team experienced in outcomes research, the scope and setting of the core set

158 nonmedical factors, and growing attention to outcomes research, there is increasing interest in the e

159 representatives from governmental agencies, outcomes research thought leaders, and public and privat

160 or anemia and hyperparathyroidism), although outcome research to support some of our current guidelin

161 orkgroup summary examines the suitability of outcomes research to complement results of randomized co

162 iews, evidence-quality appraisal, and health outcomes research to provide a methodologic framework fo

163 Recognizing the value of outcomes research to understand and bridge translational

164 th lumbar disk herniation, the Spine Patient Outcomes Research Trial (SPORT) randomized trial intent-

165 The SPORT (Spine Patient Outcomes Research Trial) reported favorable surgery outc

166 GN, SETTING, AND PATIENTS: The Spine Patient Outcomes Research Trial, a randomized clinical trial enr

167 ion cases of subjects from the Spine Patient Outcomes Research Trial.

168 al study of persons in Collaborations in HIV Outcomes Research/US cohort who initiated their first HA

169 Outcomes research utilizing evidence-based approaches ar

170 egulatory agencies generally do not consider outcomes research when assessing efficacy of new drugs o

171 ulatory and reimbursement authorities to use outcomes research when making efficacy, effectiveness, a

172 nts from the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With

173 spirin), and FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With

174 The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with

175 in the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with

176 In FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With

177 In FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With

178 In FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with

179 In the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with

180 The FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With

181 The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with

182 tion 58) and FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with

183 URIER clinical trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With

184 enrolled in FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With

185 (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With

186 in the FOURIER study (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with

187 of the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With

188 in the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With

189 notably, the FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with

190 The recent Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with

191 d hoc analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With

192 enrolled in FOURIER (Further Cardiovascular Outcomes Research With PCSK9 inhibitors in Subjects With

193 (3) investigations into the basic science of outcomes research, with an emphasis on methodological ad